Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
30 participants
OBSERVATIONAL
2002-05-31
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
NCT05753384
Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01185886
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan
NCT00526084
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia
NCT01625143
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must sign an informed consent.
* Patients will not be excluded if they are receiving chemotherapy.
* Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.
* Patients must be =\> 18 years of age.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of New Mexico
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ian Rabinowitz, MD
Role: PRINCIPAL_INVESTIGATOR
University of New Mexico
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of New Mexico
Albuquerque, New Mexico, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1602C
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.